


APPENDIX
(Marked-Up Version of the Changes Made)

In the claims:

Claim 5 has been amended as follows:

5. (amended) A compound of formula II



in which

R₁ and R₅ simultaneously or independently of one another are hydrogen, halogen, lower-alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile;

R₂ and R₄ simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group;

R₃ is R₆R₇N-C(O)-lower alkyl, [unsubstituted or] substituted aryl, aryl-lower alkyl, substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino, or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that

R₃ is not [phenyl or] phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxy carbonyl if R₂ and R₄ are hydrogen, and R₁ and R₅ are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile;


R₆ and R₇ simultaneously or independently of one another are hydrogen, lower alkyl hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring;

or a salt thereof.

Although three claims have been added by this Amendment and Election, the total number of claims now present in the subject application does not exceed the highest number previously paid for. Accordingly, no additional fee is necessitated by the added claims. However, since this Amendment and Election will be deemed to have been filed more than one month from, but within two months of, the date of the Office Action, i.e., October 11, 2001, it is respectfully requested that the period for filing a response to said Office Action be extended by one month. Hence, charge the \$110 fee required by 37 C.F.R. §1.17(a)(1) for a one-month extension of time to Deposit Account No. 19-0134 in the name of Novartis Corporation. In this connection, an additional copy of this page is appended.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921



Joseph J. Boroyian
Agent for Applicants
Reg. No. 26,631

JJB/Id

Encls.: Additional copy of Page 5
Postcard

Date: December 7, 2001